The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Reintroduction of oxaliplatin for patients with metastatic colorectal cancer refractory to standard chemotherapy regimens.
Tohru Sasaki
No relevant relationships to disclose
Mizutomo Azuma
No relevant relationships to disclose
Wasaburo Koizumi
No relevant relationships to disclose
Tomohisa Egawa
No relevant relationships to disclose
Atsushi Nagashima
No relevant relationships to disclose
Takeshi Kenmochi
No relevant relationships to disclose
Ken Shimada
No relevant relationships to disclose
Yasutaka Takinishi
No relevant relationships to disclose
Kouji Kobayashi
No relevant relationships to disclose
Yusuke Saito
No relevant relationships to disclose
Sotaro Akatsuka
No relevant relationships to disclose
Hitoshi Arioka
No relevant relationships to disclose
Norisuke Nakayama
No relevant relationships to disclose
Ken Nishimura
No relevant relationships to disclose
Seiichi Takagi
No relevant relationships to disclose
Atsushi Shirahata
No relevant relationships to disclose
Hitoshi Soda
No relevant relationships to disclose